The most common pathogenic mutation lies within the catalytic domain (G2019S) and increases kinase activity, suggesting that LRRK2 inhibitors might offer therapeutic benefit for Parkinson's disease (Greggio et al, 2006; Ozelius et al, 2006; Smith et al, 2006; Jaleel et al, 2007; Hatcher et al, 2017). The gene discussed is LRRK2; the disease is Parkinson disease.